	US 11,883,528 B2
	Compositions and methods for treating pulmonary edema or lung inflammation
David H. Ingbar, Minneapolis, MN (US); Timothy P. Rich, Duluth, MN (US); Robert J. Schumacher, Edina, MN (US); Jianxun Lei, New Brighton, MN (US); and Maneesh Bhargava, Mendota Heights, MN (US)
Assigned to Regents of the University of Minnesota, Minneapolis, MN (US)
Filed by REGENTS OF THE UNIVERSITY OF MINNESOTA, Minneapolis, MN (US)
Filed on Aug. 23, 2022, as Appl. No. 17/893,612.
Application 17/893,612 is a continuation of application No. 16/965,095, granted, now 11,458,094, previously published as PCT/US2019/016068, filed on Jan. 31, 2019.
Claims priority of provisional application 62/624,631, filed on Jan. 31, 2018.
Prior Publication US 2023/0050861 A1, Feb. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 31/198 (2006.01); A61P 11/00 (2006.01)

CPC A61K 9/0078 (2013.01) [A61K 31/198 (2013.01); A61P 11/00 (2018.01)]

3 Claims

1. A method for treating congestive heart failure in a subject, the method comprising:

administering to the pulmonary tract of the subject a composition comprising an amount of triiodothyronine (T3) effective to ameliorate lung inflammation or pulmonary edema, wherein the composition comprises:

a salt of triiodothyronine in an amount effective to provide a lung-delivered dose of from 100 ng to 2 mg; and

a pharmaceutically acceptable buffer;

wherein the composition delivered to the lung has a pH from 5.5 to 8.5 and a maximum volume of no more than 0.30 ml per 1.67 g wet lung weight per dose.